Lp(a) contribution to PCSK9-antibody benefit in ODYSSEY-OUTCOMES and FOURIER

Lp(a) meeting Prof. Jukema answers the question whether Lp(a) levels and PCSK9 inhibition are relevant for lowering CV risk, by discussing results of substudies in the FOURIER and ODYSSEY Outcomes trials.

Educational information

This lecture by Wouter Jukema was part of the EAS-endorsed satellite meeting "The imminent danger of Lp(a): Time to face the challenge" held prior to the 87th EAS congress in Maastricht

Faculty

Wouter Jukema, Professor of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

View the slides of the presentation held by Wouter Jukema